IPO - Profile


We are a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, one of the largest areas of unmet need in medicine. We aim to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. We have built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and our expertise in inner ear biology.

We are leveraging our platform to advance our pipeline of preclinical gene therapy More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$18.00 7,060,000 Positive High 54.76%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 11 Feb, 2021

Offer 12 Feb, 2021

Look Ahead

Lock Up Expiry Aug 12, 2021

IPO Terms

Offer Price $18.00
Offer Size 7M

Market Sentiments

Stock Price